P&T MEETING AGENDA: JULY 28, 2026

COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, July 28, 2026
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
Microsoft Teams **Join the meeting now** Meeting ID: 285 749 030 599 24 Passcode: tK9At9uC **Download Teams | Join on the web**	+1 858-252-2734 (United States) Phone conference ID: 979 443 568#

AGENDA

I. Call to Order and Welcome

II. Executive Session (Upon Request)

III. Old Business

a. Approval of April 2026 Meeting Minutes

IV. New Business

a. New Products to Market to be Reviewed as Single Products

i. Yuviwel® (navepegritide) – Non-PDL
ii. Icotyde™ (icotrokinra) – Non-PDL
iii. Kygevvi® (doxecitine and doxribtimine) – Non-PDL
iv. Nereus™ (tradipitant) – Gastrointestinal: Antiemetics and Antivertigo Agents: Non-Preferred
v. Idvynso™ (doravirine/islatravir) – Antiretrovirals: HIV/AIDS: Non-Preferred
vi. Bysanti™ (milsaperidone) – Central Nervous System: Antipsychotics Second-Generation (Atypical): Non-Preferred
vii. Baxfendy™ (baxdrostat) – Non-PDL

b. Vraylar® (cariprazine) – Proposed Prior Authorization Criteria Update

V. Therapeutic Classes with Recommended PDL Status Changes

a. Angiotensin-Converting Enzyme (ACE) Inhibitors
b. Angiotensin Receptor Blockers (ARBs)
c. Antiarrhythmics, Oral
d. Anticoagulants
e. Anticonvulsants

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.

f. Antidepressants, Tricyclics
g. Calcium Channel Blockers (CCBs)
h. Movement Disorders
i. Narcolepsy Agents
j. Platelet Aggregation Inhibitors
k. Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled
l. Stimulants and Related Agents

VI. Consent Agenda

a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

• 5-Alpha Reductase (5AR) Inhibitors • ACEI + Diuretic Combinations • Alpha Blockers for Benign Prostatic Hyperplasia (BPH) • Alzheimer's Agents • Angiotensin Modulator + Calcium Channel Blocker (CCB) Combinations • Anti-anginal and Anti-Ischemic • Antidepressants, Monoamine Oxidase Inhibitors (MAOIs) • Antidepressants, Other • Antidepressants, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) • Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs) • Antimigraine Agents, Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Other Agents: Acute Treatment • Antimigraine Agents, Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Other Agents: Prophylaxis, Injectable	• Antimigraine Agents, Calcitonin Gene-Related Peptide (CGRP) Inhibitors and Other Agents: Prophylaxis, Oral • Antimigraine Agents, Triptans • Antiparkinson's Agents • Antipsychotics • Anxiolytics • ARB + Diuretic Combinations • Beta-Blockers • Bladder Relaxants • Direct Renin Inhibitors • Dopamine Receptor Agonists • Lipotropics, Other • Lipotropics, Statins • Neuropathic Pain • Sedative Hypnotics • Skeletal Muscle Relaxants • Spinal Muscular Atrophy • Tobacco Cessation Products

VII. Adjournment

a. Schedule of Upcoming Meetings
   i. October 13, 2026

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to https://kyportal.medimpact.com/provider-documents/drug-information.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at https://kyportal.medimpact.com/provider-documents/pt-committee.

Copyright © 2025. MedImpact Healthcare Systems, Inc.
All rights reserved.